In a report released today, Gil Blum from Needham maintained a Buy rating on Celcuity (CELC – Research Report), with a price target of $50.00. The company's shares closed last Friday at $13.55. According to TipRanks.com, Blum has 0 stars on 0-5 stars ranking scale with an average return of -27.2% and a 8.9% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Currently, the analyst consensus on Celcuity is a Moderate Buy with an average price target of $50.00.
https://www.tipranks.com/news/blurbs/celcuity-celc-gets-a-buy-rating-from-needham?utm_source=advfn.com&utm_medium=referral
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Celcuity.
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Celcuity.